This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alpan, R. S. Articles by Pardee, A. B. Search for Related Content PubMed PubMed Citation Articles by Alpan, R. S. Articles by Pardee, A. B.

Cell Cycle-dependent Expression of TAP1, TAP2, and HLA-B27 Messenger RNAs in a Human Breast Cancer Cell Line¹

Divisions of Cell Growth and Regulation [R. S. A., A. B. P.] and Cancer Genetics [M. Z.], Dana-Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston Massachusetts 02115

Tumor cells are generally poorly responsive to immunotherapy. The results presented here suggest that antigen presentation of somatic tumor cells may be diminished greatly in quiescence and may be determined in part by growth regulation. Peptides produced by proteasomes are transported into the endoplasmic reticulum by transporter proteins TAP-1 and TAP-2, where they bind and stabilize MHC class I molecules required for antigenic presentation on the cell surface. TAP-1 and TAP-2 mRNAs were undetectable in quiescent, serum-deprived human breast cancer cells (21PT). They appeared 10 h after serum induction, near the G₁-S boundary. In contrast, HLA-B27 mRNA was biphasically up-regulated. These mRNAs were significantly down-regulated in most tissues that contain mainly terminally differentiated, nonproliferating cells. All of the investigated breast cancer cell lines showed lower expression levels of these mRNAs than did the corresponding normal cells.

¹ This work was supported by NIH Grant GM-24571.

² To whom requests for reprints should be addressed, at Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, Phone: (617) 632-3372; Fax: (617) 632-4680.

Received 6/17/96. Accepted 8/15/96.

This article has been cited by other articles:

				B. Lankat-Buttgereit and R. Tampe The Transporter Associated With Antigen Processing: Function and Implications in Human Diseases Physiol Rev, January 1, 2002; 82(1): 187 - 204. [Abstract] [Full Text] [PDF]

				Y. Gui and L. J. Murphy Insulin-Like Growth Factor (IGF)-Binding Protein-3 (IGFBP-3) Binds to Fibronectin (FN): Demonstration of IGF-I/IGFBP-3/FN Ternary Complexes in Human Plasma J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2104 - 2110. [Abstract] [Full Text]

				A. K. Johnsen, D. J. Templeton, M.-S. Sy, and C. V. Harding Deficiency of Transporter for Antigen Presentation (TAP) in Tumor Cells Allows Evasion of Immune Surveillance and Increases Tumorigenesis J. Immunol., October 15, 1999; 163(8): 4224 - 4231. [Abstract] [Full Text] [PDF]

				Z. Shi, W. Xu, F. Loechel, U. M. Wewer, and L. J. Murphy ADAM 12, a Disintegrin Metalloprotease, Interacts with Insulin-like Growth Factor-binding Protein-3 J. Biol. Chem., June 9, 2000; 275(24): 18574 - 18580. [Abstract] [Full Text] [PDF]